2-Chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine

Catalog No. :
ACTZEG419
CAS No. :
1269440-58-5
Molecular Formula :
C10H10ClIN4
Molecular Weight :
348.58

IUPAC Name:2-chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine

2-Chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$949.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine
IUPAC Name2-chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine
MDL No.MFCD28387043
Molecular FormulaC10H10ClIN4
Molecular Weight348.58
SMILESCC(N1N=C(I)C(C2=NC(Cl)=NC=C2)=C1)C
InChI KeyNVQXUVPDZGMTOH-UHFFFAOYSA-N
SynonymPyriMidine, 2-chloro-4-[3-iodo-1-(1-Methylethyl)-1H-pyrazol-4-yl]-;2-chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine;2-Chloro-4-[3-iodo-1-(1-methylethyl)-1H-pyrazol-4-yl]pyrimidine;EOS-60566;2-Chloro-4-[3-iodo-1-(1-methylethyl)-1H-pyrazol-4-yl]-pyrimi...
CAS No.1269440-58-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACTZEG419 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTZEG419 route product structure diagram
    ACTZEG4191269440-58-5 In Stock
Inquiry

2. ACTZEG419 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTZEG419 route product structure diagram
    ACTZEG4191269440-58-5 In Stock
Inquiry

Comments (0)